Core Viewpoint - BioStem Technologies, Inc. is showcasing its innovative placental-derived products for chronic wound care at the Symposium for Advanced Wound Care (SAWC) Fall meeting, emphasizing collaboration with Venture Medical, LLC to enhance patient care and streamline treatment processes [1][2]. Company Overview - BioStem Technologies focuses on the development, manufacturing, and commercialization of placental-derived products aimed at advanced wound care [1][11]. - The company utilizes its proprietary BioREtain processing method, which preserves the natural properties of perinatal tissue, ensuring the integrity of amniotic tissue components critical for wound treatment [8][11]. Product Highlights - Key products include AmnioWrap2® and Vendaje AC®, which are exclusively available through Venture Medical [3]. - The BioStem-Venture collaboration aims to provide a superior allograft platform that meets the needs of both patients and healthcare providers [3]. Event Details - The SAWC Fall meeting is taking place from September 3-6 in Las Vegas, NV, serving as a significant educational forum for healthcare professionals focused on chronic wound care [1]. - A sponsored breakfast symposium titled "Navigating the Future of Wound Care" will feature discussions on clinical evidence and best practices in wound care management [4]. Research Contributions - BioStem has three clinical and scientific posters accepted for display at the symposium, contributing to the discourse on chronic wound care [5][10]. - Research topics include comparisons of processing methods for placental tissue allografts and sterilization methods for dehydrated birth tissue [6][10]. Strategic Partnership - The collaboration with Venture Medical enhances the logistics of managing patients requiring skin substitutes for chronic wound treatment, showcasing a combined value proposition [2][3][13].

Core Insights - BioStem Technologies, Inc. reported a record first quarter in 2025, with revenue increasing by 73% year-over-year to $72.5 million, driven by strong performance in its wound care portfolio, particularly the Vendaje AC product [2][7][13] - The company is focused on transitioning more customers to Vendaje AC to enhance brand consistency and is also working on reducing selling, general, and administrative expenses by phasing out licensing fees associated with AmnioWrap2 [2][3] - BioStem has received IRB approval for a new clinical trial for its BioREtain Amnion Chorion product aimed at treating venous leg ulcers, marking its third prospective clinical trial [3][4] Financial Performance - Preliminary net revenue for Q1 2025 was $72.5 million, a 73% increase from $41.9 million in Q1 2024 [7][13] - Gross profit reached $71.7 million, representing a gross margin of 99%, compared to 95% in the same quarter of the previous year [7][13] - Operating expenses increased to $66.4 million from $35.1 million in Q1 2024, primarily due to higher sales and marketing costs [7][13] Clinical Trials and Product Development - BioStem launched the BR-AM-DFU clinical trial to evaluate Vendaje for non-healing diabetic foot ulcers, aiming to validate the clinical efficacy of its BioREtain technology [4] - The company has expanded its intellectual property portfolio, holding 55 issued patents and 52 pending patents, reinforcing its innovation leadership in regenerative medicine [5] Market Position and Strategic Focus - The company is actively pursuing an uplisting to Nasdaq and is currently under SEC review regarding its Form 10 registration [2][7] - BioStem aims to strengthen its position in the chronic wound care market while maintaining a focus on clinical evidence to support product adoption [2][3]